SCHEMBL675050

SCHEMBL675050

O=S(=O)(c1ccccc1)n1c2ccc(-c3ccc(N4CCOCC4)cn3)cc2c2ccc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 13/20 0.42
PIK3CD O00329 6/20 0.42
PIK3CB P42338 5/20 0.42
PIK3CG P48736 5/20 0.42
AKT1 P31749 3/20 0.41
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
MTOR P42345 3/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
AHR P35869 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.37
HCRTR1 O43613 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668320 0.92 PIK3CA (0.42) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL675440 0.87 PIK3CA (0.42) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL675054 0.84 PIK3CA (0.42) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL3723156 0.84 NOD2 (0.37) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL3669202 0.82 ACVR1B (0.41) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL676293 0.80 NPC1 (0.45) PIK3CDTSHRMTORALDH1A1MAPT
SCHEMBL3668236 0.78 HTR6 (0.46)
SCHEMBL3434703 0.76 NOD2 (0.37) PIK3CAPIK3CDPIK3CBPIK3CGAKT1
SCHEMBL675472 0.74 SRC (0.43)
SCHEMBL3668206 0.74 PARP1 (0.45) PIK3CDTSHRMTORALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 PIK3CA 1855/4885PIK3CD 1587/4885PIK3CB 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.